Work

Table S1, Table S1B, Table S2 from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Year: 2023

Type: other

Abstract: S1. Patient Characteristics of eligible (n=37) and MTD/RP2D evaluable (n=27) patients S1B. Diagnosis of eligible (n=37) and MTD/RP2D evaluable (n=27) patients. S2. In Cycle 1, All Hematologic and Non-Hematologic toxicities related to protocol therapy in evaluable patients (N=27)

DOI: 10.1158/1078-0432.22480001

Authors: Kristina A. Cole, Sharmistha Pal, Rachel A. Kudgus, Heba Ijaz, Xiaowei Liu, Charles G. Minard, Bruce R. Pawel, John M. Maris, Daphne A. Haas-Kogan, Stephan D. Voss, Stacey L. Berg, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361815350

Cites:

Cited by:

Related to: 10